Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients
Claire Fabre(Institut Curie), Marco Gobbi(Ospedale Policlinico San Martino), Cyrine Ezzili(Institut Curie), Mustapha Zoubir(Institut Curie), Marie-Paule Sablin(Institut Curie), Karen Small(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ellie Im(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nabeegha Shinwari(Merck & Co., Inc., Rahway, NJ, USA (United States)), Da Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Honghong Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christophe Le Tourneau(Inserm)
Cited by 50
Abstract
Related Papers
No related papers found
Powered by citation graph analysis